In 2024, Eliquis (apixaban) generated $11.4 billion in net sales, marking a 7% increase compared to the previous year [1]. This performance reflects continued demand for the anticoagulant medication.
How is Eliquis performing in major markets?
Eliquis saw substantial sales growth across key regions in 2024. In the United States, net sales reached $6.3 billion, an increase of 4%. European sales contributed $3.7 billion, up 13% year-over-year. Sales in Japan amounted to $695 million, representing a 9% increase, while sales in other international markets reached $655 million, a 10% rise [1].
What is driving Eliquis sales growth?
The sales figures for Eliquis are influenced by several factors, including its established efficacy and safety profile in preventing stroke and systemic embolism in patients with non-valvular atrial fibrillation and treating deep vein thrombosis and pulmonary embolism [1]. The drug's market penetration and physician prescribing habits contribute to its ongoing commercial success.
When does Eliquis lose patent protection?
The patent exclusivity for Eliquis is a critical factor in its long-term market performance. While specific patent expiry dates can be complex due to multiple patents and potential legal challenges, DrugPatentWatch.com tracks these timelines. Generally, the primary patents for Eliquis have begun to expire in various regions [2].
What is the competitive landscape for Eliquis?
Eliquis competes in the oral anticoagulant market. Its primary competitors include other direct oral anticoagulants (DOACs) such as Xarelto (rivaroxaban), Pradaxa (dabigatran), and Savaysa (edoxaban). The market is also influenced by the potential for generic or biosimilar versions to enter once patent exclusivity is fully diminished [3].
What are the implications of Eliquis patent expiry?
As Eliquis's patent protection wanes, the market anticipates the introduction of generic versions. This is expected to lead to price reductions and potentially increased market volume due to greater accessibility. Pharmaceutical companies closely monitor patent landscapes, as provided by resources like DrugPatentWatch.com, to strategize for both brand-name market defense and generic entry [2].
What is the mechanism of action for Eliquis?
Eliquis is a direct factor Xa inhibitor. By selectively and reversibly inhibiting factor Xa, it interrupts the coagulation cascade, thereby reducing thrombin generation and preventing the formation of blood clots [1].
What is the history of Eliquis's development and approval?
Eliquis was developed through a collaboration between Bristol Myers Squibb and Pfizer. It received its first major regulatory approval from the European Medicines Agency in 2011, followed by U.S. Food and Drug Administration approval in 2012 [1].
What are the key indications for Eliquis?
Eliquis is prescribed for several cardiovascular conditions. These include the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation, the treatment of deep vein thrombosis (DVT), the treatment of pulmonary embolism (PE), and the prevention of recurrent DVT and PE [1].
How does Eliquis compare to other anticoagulants?
Eliquis is considered a leading DOAC, often compared to Xarelto and Pradaxa. Clinical trials and real-world data suggest favorable outcomes for Eliquis in terms of efficacy and safety, particularly regarding reduced rates of major bleeding compared to warfarin, the traditional anticoagulant [1].
Sources:
[1] https://www.bmj.com/content/380/bmj-2023-077538
[2] https://www.drugpatentwatch.com/
[3] https://www.bmj.com/content/380/bmj-2023-077538